Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-12-23

FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approves a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., enabling an updated indication/label fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tradjenta (Linagliptin)

Snippet

SUPPL AP for TRADJENTA (LINAGLIPTIN)